📊 Note: Daily ratings and analytics are updated after market close and will be available by 7:00 PM IST.

Details

NameSymbolSector
SANDU PHARMACEUTICALS LTD.SANDUPHQPharmaceuticals
Open
35.5
High
35.5
Low
33.69
Close
33.69
Volume
367
Exchange
bse
Time
01-Apr-2026

Outlook

Score:  

1.5

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Sandu Pharmaceuticals is  
Marubozu
Estimated Stoploss of Sandu Pharmaceuticals is ₹  
35.5
Sandu Pharmaceuticals has a  
Bearishℹ
 pattern. 
Formation of  
Marubozu
 candle pattern indicates Sandu Pharmaceuticals has chances of  
Continuationℹ
 of the current trend. 

Trend

Sandu Pharmaceuticals is in  
Sideways trendℹ
. 
Price of Sandu Pharmaceuticals is  
Downℹ
 by  

2.66

%. 
Target
Buy @ 

31.09

Sell @ 

39.61

Current @ 

33.69

Volume

The trade volumes of Sandu Pharmaceuticals have become  
Deficientℹ
The volume trend for Sandu Pharmaceuticals is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Sandu Pharmaceuticals is  

Down

 by  

88.91

% 

Valuation

The current market price of Sandu Pharmaceuticals is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 55cr and total assets worth ₹ 55cr, the balance sheet of Sandu Pharmaceuticals is:  
Balancedℹ
. 
Cashflow
Sandu Pharmaceuticals has  
Poorℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

200

%. 

(*Mar 2025)

0% in operatingℹ
100% in investingℹ
0% in financingℹ
0% in otherℹ
Income
The income of Sandu Pharmaceuticals is  

₹ 17cr

 and  

Loss

 is :  

₹ 0cr

(*Sep 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Up by:  

6.25

% 

(*Sep 2025)

The income of Sandu Pharmaceuticals is  

₹ 16cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Up by:  

14.29

% 

(*Jun 2025)

The income of Sandu Pharmaceuticals is  

₹ 14cr

 and  

Loss

 is :  

₹ 0cr

(*Mar 2025)

Sandu Pharmaceuticals Losses increased by:  

0

% and Income is Down by:  

22.22

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.